544
Views
23
CrossRef citations to date
0
Altmetric
Drug Evaluations

Belimumab – an anti-BLyS human monoclonal antibody for rheumatoid arthritis

&
Pages 315-322 | Published online: 27 Dec 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Filipe Seguro Paula & José Delgado Alves. (2014) Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis. Biologics: Targets and Therapy 8, pages 1-12.
Read now
Homa Timlin & Clifton O Bingham$suffix/text()$suffix/text(). (2014) Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis. Expert Opinion on Biological Therapy 14:7, pages 893-904.
Read now
Lukas Bossaller & Achim Rothe. (2013) Monoclonal antibody treatments for rheumatoid arthritis. Expert Opinion on Biological Therapy 13:9, pages 1257-1272.
Read now

Articles from other publishers (20)

Giovanni Orsolini, Francesca Mastropaolo, Eleonora Favaro, Anna Piccinelli, Davide Bertelle, Ombretta Viapiana, Maurizio Rossini & Riccardo Bixio. (2023) Ultrasonographic non-radiographic erosions could predict the efficacy of belimumab in articular systemic lupus erythematosus. Clinical Rheumatology 42:11, pages 3083-3088.
Crossref
Jingyue Li, Mingjiu Zhao, Wenjun Luo, Jiaqi Huang, Bin Zhao & Zhiguang Zhou. (2023) B cell metabolism in autoimmune diseases: signaling pathways and interventions. Frontiers in Immunology 14.
Crossref
Nikolaos Kintrilis, Fotini Gravani, Anna Rapti, Myrto Papaioannou, Christina-Maria Flessa, Adrianos Nezos, Eleni Antypa, Ioanna Papadaki, Τheofanis Karageorgas, Haralampos M Moutsopoulos & Clio P Mavragani. (2023) Subclinical atherosclerosis profiles in rheumatoid arthritis and primary Sjögren’s syndrome: the impact of BAFF genetic variations . Rheumatology 62:2, pages 958-968.
Crossref
Borja Hernández-Breijo, Ioannis Parodis, Marta Novella-Navarro, Ana Martínez-Feito, Victoria Navarro-Compán, Mariana Díaz-Almirón, Dora Pascual-Salcedo, Alejandro Balsa & Chamaida Plasencia-Rodríguez. (2022) Low Serum BAFF Concentration Is Associated with Response to TNF Inhibitors in Seropositive Patients with Rheumatoid Arthritis. Journal of Clinical Medicine 11:17, pages 5207.
Crossref
Yidan Zhang, Jie Tian, Fan Xiao, Leting Zheng, Xiaoxia Zhu, Ling Wu, Cheng Zhao, Shengjun Wang, Ke Rui, Hejian Zou & Liwei Lu. (2022) B cell-activating factor and its targeted therapy in autoimmune diseases. Cytokine & Growth Factor Reviews 64, pages 57-70.
Crossref
Xinxin Chen, Yanqiu Wang, Yicheng Qi, Jiqi Yan, Fengjiao Huang, Mengxi Zhou, Weiqing Wang, Guang Ning, Yulin Zhou & Shu Wang. (2021) Expansion of inflammatory monocytes in periphery and infiltrated into thyroid tissue in Graves’ disease. Scientific Reports 11:1.
Crossref
Wolfgang Schuh, Dirk Mielenz & Hans-Martin Jäck. 2020. 57 107 .
Ricardo A. BattaglinoNguyen NguyenMegan SummersLeslie R. Morse. (2019) B Cell–Activating Factor Is Associated with Testosterone and Smoking Status in Non-Ambulatory Men with Chronic Spinal Cord Injury. Journal of Neurotrauma 36:24, pages 3332-3337.
Crossref
Arezoo G. Shabgah, Zhaleh Shariati‐Sarabi, Jalil Tavakkol‐Afshari & Mojgan Mohammadi. (2019) The role of BAFF and APRIL in rheumatoid arthritis. Journal of Cellular Physiology 234:10, pages 17050-17063.
Crossref
Paloma Valentina Castillo Dayer, Nuria Lozano Rivas, Javier José Martínez Ferrín, Ana Mercedes Victoria Martínez, Paloma Sánchez‐Pedreño Guillen & Carlos Marras Fernández‐Cid. (2019) Belimumab treatment in rhupus: A case report with severe skin involvement. Dermatologic Therapy.
Crossref
Fang Wei, Yan Chang & Wei Wei. (2015) The role of BAFF in the progression of rheumatoid arthritis. Cytokine 76:2, pages 537-544.
Crossref
Yan Huang, Xiaohong Fu, Xilin Lyu, Zhizhen Xu, Zhicheng He, Yan Zhang, Yijun Zeng, Fengtian He & Gang Huang. (2015) Activation of LXR attenuates collagen-induced arthritis via suppressing BLyS production. Clinical Immunology 161:2, pages 339-347.
Crossref
Karin Kannel, Kristi Alnek, Liina Vahter, Katrin Gross-Paju, Raivo Uibo & Kalle V. Kisand. (2015) Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome. PLOS ONE 10:11, pages e0143393.
Crossref
Yacong Zhao, Xiafei Hao, Jiannan Feng, Beifen Shen, Jing Wei & Jian Sun. (2015) The comparison of BLyS-binding peptides from phage display library and computer-aided design on BLyS?TACI interaction. International Immunopharmacology 24:2, pages 219-223.
Crossref
Bert A. ‘t Hart, S. Anwar Jagessar, Yolanda S. Kap, Krista G. Haanstra, Ingrid H.C.H.M. Philippens, Che Serguera, Jan Langermans & Michel Vierboom. (2014) Improvement of preclinical animal models for autoimmune-mediated disorders via reverse translation of failed therapies. Drug Discovery Today 19:9, pages 1394-1401.
Crossref
Maria Greenwald, Leszek Szczepanski, Alastair Kennedy, Melissa Veenhuizen, Wendy J Komocsar, Emery Polasek, Kelly Guerrettaz, Pierre-Yves Berclaz & Chin Lee. (2014) A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis. Arthritis Research & Therapy 16:4.
Crossref
Amina A. Mahdy, Hala A. Raafat, Hussein S. El-Fishawy & Tamer A. Gheita. (2014) Therapeutic potential of hydroxychloroquine on serum B-cell activating factor belonging to the tumor necrosis factor family (BAFF) in rheumatoid arthritis patients. Bulletin of Faculty of Pharmacy, Cairo University 52:1, pages 37-43.
Crossref
Guo-dong Feng, Xiao-chang Xue, Mei-li Gao, Xian-feng Wang, Zhen Shu, Nan Mu, Yuan Gao, Zeng-lu Wang, Qiang Hao, Wei-na Li, Meng Li, Cun Zhang, Wei Zhang & Ying-qi Zhang. (2014) Therapeutic Effects of PADRE-BAFF Autovaccine on Rat Adjuvant Arthritis. BioMed Research International 2014, pages 1-9.
Crossref
Ignacio Sanz. 2014. Drugs Targeting B-Cells in Autoimmune Diseases. Drugs Targeting B-Cells in Autoimmune Diseases 37 64 .
Gaurav Malviya, Simonetta Salemi, Bruno Laganà, Andrea Picchianti Diamanti, Raffaele D’Amelio & Alberto Signore. (2013) Biological Therapies for Rheumatoid Arthritis: Progress to Date. BioDrugs 27:4, pages 329-345.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.